Karasawa A, Kubo K, Shuto K, Oka T, Nakamizo N
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.
Arzneimittelforschung. 1988 Nov;38(11A):1698-701.
Using gallamine-immobilized cats, the effect of (+/-)-(R*)-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dic arb oxylic acid (R*)-1-benzyl-3-piperidinyl ester, methyl ester hydrochloride (benidipine hydrochloride, KW-3049) was compared with those of other drugs in terms of the propensity for atrioventricular conduction disturbances and orthostatic hypotension. The administration of KW-3049 at doses of 1 to 300 micrograms/kg i.v. dose-dependently lowered the blood pressure and also reduced the heart rate. In terms of the maximum blood pressure lowering activity, KW-3049 was similar in degree to nifedipine and approximately 30 times as potent as diltiazem, verapamil and phenoxybenzamine. KW-3049 as well as nifedipine, at doses with which the mean blood pressure can be reduced by 50 mmHg, hardly affected the PR-interval of ECG, whereas diltiazem and verapamil at their hypotensive doses markedly prolonged the PR interval. These four calcium antagonists at their high doses elicited 2nd or 3rd degree atrioventricular blocks in some cases. On the other hand, phenoxybenzamine did not affect the atrioventricular conduction at its hypotensive doses. Inhibitory action on the pressor responses to head-up tilting in cats was observed neither in KW-3049, nifedipine, verapamil nor diltiazem. On the contrary, phenoxybenzamine strongly inhibited the orthostatic pressor reflexes. From these results, it was suggested that in terms of the prolongation action of atrioventricular conduction KW-3049 is less potent than diltiazem and verapamil but similar in degree to nifedipine, and that KW-3049 is not likely to cause orthostatic hypotension.
使用加拉明固定的猫,比较了(±)-(R*)-2,6-二甲基-4-(间硝基苯基)-1,4-二氢吡啶-3,5-二羧酸(R*)-1-苄基-3-哌啶酯盐酸甲酯(盐酸贝尼地平,KW-3049)与其他药物在房室传导障碍倾向和体位性低血压方面的作用。静脉注射1至300微克/千克剂量的KW-3049可使血压剂量依赖性降低,同时也使心率降低。就最大降压活性而言,KW-3049的程度与硝苯地平相似,效力约为地尔硫卓、维拉帕米和酚苄明的30倍。KW-3049以及硝苯地平,在能使平均血压降低50 mmHg的剂量下,几乎不影响心电图的PR间期,而地尔硫卓和维拉帕米在其降压剂量下可显著延长PR间期。这四种钙拮抗剂在高剂量时在某些情况下会引发二度或三度房室传导阻滞。另一方面,酚苄明在其降压剂量下不影响房室传导。在KW-3049、硝苯地平、维拉帕米和地尔硫卓中均未观察到对猫头高位倾斜升压反应的抑制作用。相反,酚苄明强烈抑制体位性升压反射。从这些结果表明,就房室传导的延长作用而言,KW-3049比地尔硫卓和维拉帕米效力低,但程度与硝苯地平相似,并且KW-3049不太可能引起体位性低血压。